Incepta began its operation with a handful of highly skilled and dedicated professionals guided by an able leadership. Proper strategic planning, technical excellence, swift and timely decisions helped us achieve our objectives leading to much faster growth. Incepta was able to anticipate the need of the market and provide the right product at the right time. High focus on R&D investment from the very beginning made possible the introduction of quality products ahead of its competitors in most cases.
Incepta Pharmaceuticals Ltd. is now the 2nd largest company of the country and recognized as the fastest growing of the top five manufacturing company in the country. Established in the year 1999, the company has come a long way.
Currently the Zirabo and Dhamrai plant consists of several buildings with state of the art technology. There are dedicated cephalosporin manufacturing building, a specialized manufacturing building for the production of lyophilized products, insulin and amino acids and liquid and semisolid manufacturing building and also large warehouse in those facilities.
Currently all the products are coming from these two plant at Zirabo and Dhamrai. The company now produces almost all types of dosage forms covering nearly all therapeutic area.
Incepta now has one of the largest and competent sales force and large distribution network of its own, operated from 23 different locations throughout the country. A most dynamic skilled and dedicated marketing team comprising of pharmacists and doctors are at the core of the marketing operation. These highly skilled professionals play a crucial role in providing the necessary strategic guideline for the promotion of its product.
Incepta Heabal and Nutricare Ltd, a sister concern of Incepta Pharmaceutical Ltd, introduces first ever probiotic brand Luvena, a strain specific Probiotic combination of Lactobacillus Rhamnosus GR-1 & Lactobacillus Reuteri RC-14 for the first time in Bangladesh. Each capsule contains 2.3 billion live bacteria and is indicated for the treatment of Urinary Tract Infection and Vaginal Infection. This is the worlds’ most documented Probiotic strain combination specially designed for women health.
Incepta Pharmaceuticals Ltd received National Export Trophy in the pharmaceuticals products category for the fiscal year 2014-15 and 2015-2016 for its outstanding performance in the country’s export earnings. This consecutive winning of National Export Trophy, recognizes the continuous growth and new market exploration in many parts of the world.
In this year, Incepta Animal Health Division (Sister Concern of Incepta Pharmaceuticals Ltd) introduced locally manufactured economically important FMD (Foot and Mouth Disease) vaccine.
In 2018, Incepta Pharmaceuticals Ltd achieved another international certification, FREISTAAT SACHSEN, the regulatory authority of Germany inspected the Dhamrai plant of Incepta Pharmaceuticals Ltd in March 2018. Incepta received the GMP approval certificate for its solid dosage form facility on 16th May 2018 for its own formulated products allowing marketing in Germany and other European countries.
In 2018, the company launched 55 products, 10 of which first ever in Bangladesh.
Incepta Animal Health Division (Sister Concern of Incepta Pharmaceuticals Ltd) launched a series of poultry vaccine in Bangladesh market. The Brand names of Vaccines are RaniVax Plus Initial, RaniVax Plus Booster, GumboMed and GumboMed Plus.
In August 2017, Incepta Hygine & Hospicare Ltd, a sister concern of Incepta Pharmaceuticals Ltd launched the most advanced adult diaper with the brand name Aspire.
In this year the company had been awarded National Export Trophy in the pharmaceuticals products category for the fiscal year 2013-14 for their outstanding performance in the country’s export earnings.
In 2017, the company launched 27 products, 5 of which were first ever in Bangladesh.
Incepta Vaccine Ltd had launched its vaccine bulk manufacturing facility in Savar, Dhaka. Honorable health Minister Mohammed Nasim, MP inaugurated the facility on 28 July 2016.
Incepta launched 3 mAbs with brand name Relyto 100 & 500 (Rituximab), Denosis 60 & 120 (Denosumab) and Advixa (Adalimumab) first ever locally manufactured monoclonal antibodies (MAB) in Bangladesh market.
On November 2016, The Company launched its first anticancer product Erlotinib 100 mg & 150 mg with brand name Erlocent 100 & 150.
In this year, the company launched 41 products, 11 of which were first ever in Bangladesh.
The Company launched Animal Health products in March 2015. A fully dedicated plant had engaged for Animal Health products manufacturing.
The company was under focus of global media after launching of Hopetavir (1st generic Sofosbuvir of the world), a life-saving anti-viral drug used to treat Chronic Hepatitis-C infection in adults.
Incepta Vaccine Ltd had introduced snake venom antiserum for the first time in Bangladesh with the brand name of Antivenom.
Incepta Pharmaceuticals Ltd launched the world’s first ever generic drug of Ledipasvir + Sofosbuvir tablet in Bangladesh market.
In 2015, the company launched 36 products, 5 of which were first ever in Bangladesh.
In February 2014, Incepta Hygine & Hospicare Ltd, a sister concern of Incepta Pharmaceuticals Ltd launched the most advanced baby diaper with the brand name NeoCare.
In this year, the company had launched 22 products, 3 of which were first ever in Bangladesh.
Incepta Vaccine Ltd, a sister concern of Incepta Pharmaceuticals Ltd had introduced Rabies Immunoglobulin first time in Bangladesh with the brand name of Rabix-IG as well as it also introduced Vaxitet-IG for the first time in Bangladesh market.
UKMHRA certificate had been renewed in this year.
In 2013 the company launched 40 products, 7 of which were first ever in Bangladesh market.
In January 2012, Vaccine plant officially inaugurated by the Honorable Health & Family Welfare Minister Prof. Dr. A. F. M. Ruhal Haque MP.
Incepta Vaccine Ltd, a sister concern of Incepta Pharmaceuticals Ltd had introduced locally manufactured Hepatitis B vaccine first time in Bangladesh with the brand name of Hepa-B.
A protocol agreement was signed between Incepta Pharmaceuticals Ltd and the Department of the Public Health of the Republic of Belarus for co-operation and production of pharmaceuticals.
In 2012 the company launched 52 products, 7 of which were first ever in Bangladesh market.
Incepta implemented globally acclaimed ERP software system SAP. Incepta is the first Bangladeshi Pharmaceutical company to implement SAP to manage resources throughout the company operation.
Incepta received new license, Incepta Vaccine Ltd, to manufacture vaccine for the first time in Bangladesh and introduced human vaccines including Vaxphoid, Rabix-VC and Vaxitet in Bangladesh market.
UK MHRA, the regulatory authority of England inspected the Zirabo plant of Incepta Pharmaceuticals Ltd in February 2011. Incepta received the GMP approval certificate for its solid dosage form facility on 20th July 2011 for its own formulated products allowing marketing in UK and other European countries.
A contract manufacturing agreement had been signed between Sanofi-Aventis Bangladesh Limited and Incepta Pharmaceuticals Ltd. Under this agreement shall manufacture and supply Sanofi-Aventis Bangladesh Limited one of its global brands Clexane.
Incepta was accepted and became enlisted with the Copenhagen office of UNICEF, UNDP and UNESCO as global supplier of medicine.
Incepta was awarded GMP certificate from Uganda, National Drug Authority on 5th August 2010 (Sterile Products, Non-sterile products and Cephalosporins).
0Incepta launched 56 product presentations, 10 of which were first ever in Bangladesh market.
Incepta started venturing in the field of human vaccines and hormonal products. Construction of the Vaccine & Hormones facilities started on 1st January 2009 and 8th November 2009 respectively.
Incepta became the first Bangladeshi Company to get GMP Compliance Certificate from Turkey (Tablets, Capsules and Lyophilized products) on January 08, 2009.
Incepta achieved GMP certification from the Ministry of Health, Yemen on May 25, 2009 (Sterile and Non-sterile products).
Incepta launched 51 new products in 2009, 4 of these were first ever in Bangladesh pharmaceutical market. The company maintained the 2nd largest (IMS) position in 2009.
Continued investment in our core strength manufacturing plant led to recognition from European authorities and on January 11, 2008 Incepta attained European "Certificate of GMP Compliance".
40 new products with 86 presentations were introduced of which 10 were first ever in Bangladesh.
Incepta Zirabo plant received GMP certification (General formulations and Cephalosporins) from Kenyan Ministry of Health on January 21, 2008.
Incepta was also awarded GMP (Cephalosporins) from Ethiopian Ministry of Health on July 22, 2008.
Incepta registered 51 products in Mongolia on September 26, 2008 (As first Bangladeshi Company).
Incepta registered 3 products in Georgia on October 13, 2008 (As first Bangladeshi Company).
In 2008 significant number of products got registration in overseas countries. 19 products from Democratic Republic of Congo, 20 products from Sri Lanka, 22 products from Togo, 8 products from Hong Kong, 20 products from Mauritania, 6 products from Vietnam and 1 product in Cambodia.
The company became the 2nd largest (IMS) among the companies operating in Bangladesh.
Incepta pioneered the introduction of biotech products (Human Insulin) and lyophilized products (Pantoprazole injection) in the Bangladesh pharmaceutical market. This was the first time for a local pharmaceutical company to produce such highly sophisticated technology product in the country.
A total of 32 new generics with 82 presentations were launched. 4 of these generics were first ever in Bangladesh.
Marketing, Sales, Distribution and Administration departments shifted to the fully owned new office premises in Tejgaon, Dhaka. The international standard head office of Incepta started operation in the new office premises from 1st October, 2007.
A marketing and sales team was setup in Myanmar headed by a country manager from the Marketing Strategy Department to promote 35 products registered with the Myanmar FDA.
By 2006 Incepta had positioned itself as an innovative research oriented and knowledge based pharmaceutical company specializing in analysis, design and development of new products.
Incepta successfully started overseas marketing operation from May 2006.
A total of 25 new generics with 82 presentations were launched. 9 of these generics were first ever in Bangladesh.
The company maintained the ranking of 3rd largest in the country (IMS).
We thrived under challenge and excelled in venturing into unexplored grounds and continued to satisfy our customers. Incepta was audited and accepted as a supplier for UNICEF & UNDP. We started to supply life saving drugs to UNICEF from March, 2005.
A total of 27 new generics with 76 presentations were launched. 12 of these generics were introduced first ever in Bangladesh.
The company was ranked 3rd largest in the country (IMS).
A total of 17 new generics with 32 presentations were launched, 6 of these generics were first ever in Bangladesh.
The company ranked the 5th largest company of the country (IMS).
Incepta kept on introducing innovative and newer molecules to the local market. A total of 32 new generics with 48 presentations were launched. 18 of these generics were first ever in Bangladesh.
The new office (Dhanmondi) for the sales and distribution operation was inaugurated.
By the end of the year Incepta was ranked 8th company of the country (IMS).
A total of 32 new generics with 49 presentations were launched. 14 of these generics were first ever in Bangladesh.
Massive expansion project of the factory was envisioned. New office for the sales and distribution operation was also taking shape.
By the end of the year Incepta was ranked 10th company of the country (IMS).
December 16th 1998, the construction of the factory began located at Zirabo, Savar, Dhaka.
August 1999, office operations began.
December 1999, first product was manufactured from Incepta Pharmaceuticals Ltd’s manufacturing plant.
January 2000, sales began formally.
February 2000, training of the first batch of medical representatives began.
April 2000, with launching of Osartil (Losartan Potassium) the first prescription product of Incepta was launched in the market. The company started off in a new direction.
Several other first ever product like; Celenta (Celecoxib), Rofenta (Rofecoxib) and Omidon (Domperidone) followed the footsteps of Osartil.
A total of 23 new generics with 35 presentations were launched in 2000. 4 of these generics were first ever in Bangladesh.
By the end of 2000 Incepta was ranked 31st company of the country (IMS).
There was massive restructuring throughout the company. Sales, Distribution, Marketing Strategy Department, and Factory; all were reorganized.
A total of 18 new generics with 37 presentations were launched this year. 11 of these generics were first ever in Bangladesh.
By the end of the year 2001, Incepta was ranked 12th company of the country.
From the very beginning Incepta has focused on launching newer and innovative products. High investment in R&D and advanced technology has allowed the company to launch 455 generics with 843 presentations, 167 of which were introduced "first ever in Bangladesh". Incepta and its sister concerns are now manufacturing Human vaccines, Monoclonal antibodies, Biotech products, Hormones, Natural products, Animal health products, Hygiene products and Hospital devices in wide range of dosage forms. Acceptance of these high quality products led to the company caring 2nd position among Pharma companies within 8 years of starting operation.
|Year||No. of Products||First Ever Product||IMS Rank*|